{"id":"doxazosin-extended-release","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Dizziness"},{"rate":"8-12","effect":"Fatigue"},{"rate":"5-10","effect":"Headache"},{"rate":"5-8","effect":"Hypotension"},{"rate":"1-2","effect":"Syncope"},{"rate":"3-5","effect":"Rhinitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Doxazosin blocks alpha-1 adrenergic receptors on smooth muscle cells in the prostate, bladder neck, and blood vessels. This causes vasodilation and smooth muscle relaxation, reducing urinary obstruction symptoms in benign prostatic hyperplasia and lowering systemic vascular resistance to reduce blood pressure in hypertension. The extended-release formulation provides sustained drug delivery for once-daily dosing.","oneSentence":"Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:59.732Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Benign prostatic hyperplasia with lower urinary tract symptoms"},{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT03339258","phase":"PHASE2","title":"A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD","status":"ACTIVE_NOT_RECRUITING","sponsor":"San Francisco Veterans Affairs Medical Center","startDate":"2018-04-15","conditions":"Stress Disorders, Post-Traumatic","enrollment":80},{"nctId":"NCT01371851","phase":"PHASE1, PHASE2","title":"Doxazosin for Psychostimulant Dependence","status":"COMPLETED","sponsor":"University of Arkansas","startDate":"2011-06","conditions":"Methamphetamine or Cocaine Dependence","enrollment":22},{"nctId":"NCT00661895","phase":"PHASE4","title":"Black Education and Treatment of Hypertension (BEAT HTN)","status":"COMPLETED","sponsor":"Creighton University","startDate":"2005-08","conditions":"Hypertension","enrollment":99}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Cardozin XL 4mg Prolonged-release Tablets","Cardura XL","Cardura"],"phase":"marketed","status":"active","brandName":"Doxazosin extended release","genericName":"Doxazosin extended release","companyName":"University of Arkansas","companyId":"university-of-arkansas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Doxazosin is an alpha-1 adrenergic receptor antagonist that relaxes smooth muscle in the prostate and bladder neck to improve urinary flow, and also dilates blood vessels to lower blood pressure. Used for Benign prostatic hyperplasia with lower urinary tract symptoms, Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}